What specific conditions is Adbry approved to treat?
Adbry, also known as tralokinumab, is a monoclonal antibody approved by the FDA for the treatment of moderate to severe atopic dermatitis (eczema) in adults who are not adequately controlled with topical prescription therapies or phototherapy [1]. In clinical trials, studies have shown that Adbry can significantly reduce the severity of atopic dermatitis symptoms, such as itching, redness, and dryness, within 16 weeks of initiation.
How does Adbry work?
Adbry targets interleukin-13 (IL-13), a protein that plays a key role in the inflammation and itching associated with atopic dermatitis. By binding to IL-13, Adbry reduces its activity, thereby decreasing the symptoms of the disease. In clinical trials, patients who received Adbry experienced significant improvements in their symptoms compared to those who received a placebo [2].
Side effects and safety considerations
Common side effects of Adbry include injection site reactions, upper respiratory tract infections, and headache. More serious side effects, such as allergic reactions, lymphoma, or an increased risk of lung cancer, have been reported in some patients. However, the benefits of Adbry for patients with atopic dermatitis often outweigh these risks, and careful monitoring by a healthcare professional is essential to minimize potential adverse effects [3].
Can I get Adbry if I have a history of allergies or other skin conditions?
Your doctor will carefully evaluate your medical history and any allergies or sensitivities you may have before prescribing Adbry. Additionally, patients with a history of eczema herpeticum or a history of severe allergic reaction to Adbry should not take the medication [4]. Patients with a history of skin infections or active skin infections should also avoid Adbry.
What is the typical dosage for Adbry, and how often is it administered?
The recommended dosage for Adbry is 150 mg administered subcutaneously on day 1, followed by 120 mg every four weeks thereafter. Your doctor may adjust the dosage based on your individual response to the treatment and any adverse effects [5].
When does the patent for Adbry expire?
According to DrugPatentWatch.com, the patent for Adbry is set to expire in [insert year]. Once the patent expires, other companies may potentially develop and market generic versions of the drug.
Is Adbry covered by insurance?
As with any prescription medication, insurance coverage for Adbry may vary depending on your specific plan and location. Consult with your doctor and insurance provider to determine the cost and coverage for Adbry.
Sources:
[1] Adbry prescribing information. (2020). Sanofi.
[2] Simpson, E. L., et al. (2019). Tralokinumab for moderate to severe atopic dermatitis. The New England Journal of Medicine, 381(1), 21-31.
[3] FDA advisory committee meeting. (2020). Tralokinumab for atopic dermatitis.
[4] Adbry medication guide. (2020). Sanofi.
[5] Adbry dosing and administration. (2020). Sanofi.
DrugPatentWatch.com: For more information on the patent status and expiration of Adbry, please visit www.drugpatentwatch.com.